With the positive outcome from the demonstrated efficacy of limiting tumour growth with combination treatment of IDO1 inhibition and chemotherapy drug(s) in in vivo and in vivo studies, 97 different clinical trials have been reported in ClinicalTrials.gov examining combination therapy in patients with cancers [144]. Here, IDO1 is linked to neoplasm.